[177Lu]-PSMA-617放射性核素治疗转移性去势抵抗性前列腺癌:单中心、单臂、2期研究
这项单中心单臂2期试验纳入30例经标准治疗(含紫杉类化疗及二代抗雄激素)进展的转移性去势抵抗性前列腺癌患者,给予最多4周期[177Lu]-PSMA-617治疗。结果显示57%患者PSA下降≥50%,无治疗相关死亡,最常见毒性为1级口干(87%),3/4级血小板减少占13%;节点或内脏病灶客观缓解率82%(可测量病灶者),疼痛及整体健康均有改善。
要点
- 经多线治疗进展的mCRPC患者中,[177Lu]-PSMA-617的PSA应答率(≥50%下降)为57%。
- 常见毒性为1级口干(87%)、短暂恶心(50%)和疲乏(50%),3/4级血小板减少占13%。
- 可测量病灶患者客观缓解率达82%,疼痛及整体健康评分有临床意义改善。
核心结论
- [177Lu]-PSMA-617在经标准治疗进展的mCRPC患者中显示高应答率、低毒性和疼痛减轻。
- 研究结果支持开展随机对照试验,以进一步评估其与当前标准治疗的疗效对比。
研究设计与样本
- 单中心、单臂、2期试验,在澳大利亚墨尔本Peter MacCallum癌症中心开展。
- 筛查43例,纳入30例经标准治疗(含紫杉类化疗和二代抗雄激素)后进展的mCRPC患者。
- 主要终点为PSA应答(较基线下降>50%)和毒性(CTCAE),次要主要终点包括影像学应答和生活质量。
主要发现
- 30例中17例(57%,95%CI 37-75)达到PSA下降≥50%。
- 无治疗相关死亡;最常见毒性为1级口干26例(87%)、1-2级短暂恶心15例(50%)、1-2级疲乏15例(50%)。
- 可能与[177Lu]-PSMA-617相关的3或4级血小板减少发生于4例(13%)。
- 17例可测量病灶患者中14例(82%)达到节点或内脏病灶客观缓解。
关键数值与推荐
- PSA应答定义为较基线下降>50%,依据前列腺癌临床试验工作组标准。
- 入组要求ECOG体能状态评分≤2,并经PSMA和FDG-PET/CT确认高PSMA表达。
- 进展定义为影像学进展(RECIST或骨扫描)或影像学可见病灶区域新发疼痛。
临床怎么用
- 对于经紫杉类化疗和二代抗雄激素治疗后进展且高PSMA表达的mCRPC患者,[177Lu]-PSMA-617可作为候选治疗选择。
- 治疗期间需监测口干、恶心、疲乏及血小板减少等毒性。
- 该疗法可能改善疼痛和整体健康评分,适用于症状负担明显的患者。
局限性
- 单中心、单臂、2期设计,样本量小(30例),无随机对照。
- 缺乏与当前标准治疗的直接比较。
- 随访时间限于治疗完成后3个月内。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Progressive metastatic castration-resistant prostate cancer is a highly lethal disorder and new effective therapeutic agents that improve patient outcomes are urgently needed. Lutetium-177 [177Lu]-PSMA-617, a radiolabelled small molecule, binds with high affinity to prostate-specific membrane antigen (PSMA) enabling beta particle therapy targeted to metastatic castration-resistant prostate cancer. We aimed to investigate the safety, efficacy, and effect on quality of life of [177Lu]-PSMA-617 in men with metastatic castration-resistant prostate cancer who progressed after standard treatments. METHODS: In this single-arm, single-centre, phase 2 trial, we recruited men (aged 18 years and older) with metastatic castration-resistant prostate cancer and progressive disease after standard treatments, including taxane-based chemotherapy and second-generation anti-androgens, from the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Patients underwent a screening PSMA and FDG-PET/CT to confirm high PSMA-expression. Eligible patients had progressive disease defined by imaging (according to Response Evaluation Criteria In Solid Tumours [RECIST] or bone scan) or new pain in an area of radiographically evident disease, and were required to have an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or lower. Eligible patients received up to four cycles of intravenous [177Lu]-PSMA-617, at six weekly intervals. The primary endpoint was PSA response according to Prostate Cancer Clinical Trial Working Group criteria defined as a greater than 50% PSA decline from baseline and toxicity according to CTCAE. Additional primary endpoints were imaging responses (as measured by bone scan, CT, PSMA, and FDG PET/CT) and quality of life (assessed with the EORTC-Q30 and Brief Pain Inventory-Short Form questionnaires), all measured up to 3 months post completion of treatment. This trial is registered with the Australian New Zealand Clinical Trials Registry, number 12615000912583. FINDINGS: Between Aug 26, 2015, and Dec 8, 2016, 43 men were screened to identify 30 patients eligible for treatment. 26 (87%) had received at least one line of previous chemotherapy (80% docetaxel and 47% cabazitaxel) and 25 (83%) received prior abiraterone acetate, enzalutamide, or both. The mean administered radioactivity was 7·5 GBq per cycle. 17 (57%) of 30 patients (95% CI 37-75) achieved a PSA decline of 50% or more. There were no treatment-related deaths. The most common toxic effects related to [177Lu]-PSMA-617 were grade 1 dry mouth recorded in 26 (87%) patients, grade 1 and 2 transient nausea in 15 (50%), and G1-2 fatigue in 15 (50%). Grade 3 or 4 thrombocytopenia possibly attributed to [177Lu]-PSMA-617 occurred in four (13%) patients. Objective response in nodal or visceral disease was reported in 14 (82%) of 17 patients with measurable disease. Clinically meaningful improvements in pain severity and interference scores were recorded at all timepoints. 11 (37%) patients experienced a ten point or more improvement in global health score by the second cycle of treatment. INTERPRETATION: Our findings show that radionuclide treatment with [177Lu]-PSMA-617 has high response rates, low toxic effects, and reduction of pain in men with metastatic castration-resistant prostate cancer who have progressed after conventional treatments. This evidence supports the need for randomised controlled trials to further assess efficacy compared with current standards of care. FUNDING: None.
引用
- Hofman MS, Violet J, Hicks RJ, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018. PMID: 29752180. doi:10.1016/S1470-2045(18)30198-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。